BioStock publishes the Q3 2026 edition of State of Nordic Biopharma

By Modular Finance

The Nordic life science index ended the third quarter of the year broadly flat (Nordic HC SEK GI +0.27%), while the market was marked by billion-dollar licensing deals on the one hand and phase III setbacks on the other. This is according to the latest edition of BioStock's quarterly analysis State of Nordic Biopharma, published today.

Three of the quarter's four largest transactions were licensing deals. Novo Nordisk in-licensed Hengrui's oral GLP-1/GIP agonist for up to USD 2.6 billion, while AlzeCure Pharma out-licensed to QuantumCell (above USD 2.2 billion) and Nanexa to Novo (up to EUR 1.165 billion). In addition, AstraZeneca invested USD 2 billion in Summit Therapeutics.

The quarter's largest single-stock move came from Nanexa, which rose 177% following its PharmaShell licence with Novo.

At the same time, the setbacks at times seemed to line up: AstraZeneca's Wainua missed in ATTR-CM, Novo's ZEUS trial returned a hazard ratio of 0.99, and Ascelia Pharma and Xspray Pharma each received a Complete Response Letter (CRL) from the FDA. The two large caps nonetheless delivered in their second-quarter reports, with Novo raising its full-year outlook and AstraZeneca reconfirming its guidance. Among smaller companies, Alligator Bioscience stopped development of mitazalimab, Episurf Medical is winding down its medtech business, 2cureX was delisted and Magle Chemoswed proposed a voluntary delisting.

Looking ahead to the fourth quarter, the December PDUFA dates for Camurus and Hansa Biopharma and Cinclus Pharma's expected phase III topline results are highlighted as key events.

The State of Nordic Biopharma | 2026:Q3 is available at https://biostock.se/en/2026/10/a-quarter-of-billion-euro-licences-a-novo-comeback-and-a-flat-nordic-index-the-state-of-nordic-biopharma-2026q3-2/

Follow BioStock
Read the latest news, keep track of upcoming events, explore BioStock Analytics' in-depth analyses and watch the latest videos! Subscribe to our newsletters at https://www.biostock.se/newsletter 
Follow BioStock on social media: LinkedIn and Facebook!  
 
About BioStock 
BioStock is the Nordic region's leading information channel for life science. Focusing on biotech, medtech, diagnostics and pharmaceutical development, we provide daily news updates, in-depth analyses via BioStock Analytics, exclusive interviews and innovation-driving networking events – all to keep you up to date on developments in the sector.
BioStock – Connecting Innovation & Capital. 

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.